8,180 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,180 shares of the specialty pharmaceutical company's stock, valued at approximately $244,000.

Several other institutional investors have also added to or reduced their stakes in COLL. Wealthquest Corp bought a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at $62,000. Janney Montgomery Scott LLC bought a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at $439,000. SummerHaven Investment Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 1.9% during the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock valued at $727,000 after buying an additional 448 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Collegium Pharmaceutical by 4.2% during the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company's stock valued at $426,000 after buying an additional 578 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 4.5% during the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after buying an additional 477 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Piper Sandler restated a "neutral" rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.75.

Insider Buying and Selling

In related news, Director John Gordon Freund sold 6,601 shares of Collegium Pharmaceutical stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the completion of the sale, the director directly owned 70,658 shares in the company, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Down 2.4%

NASDAQ:COLL traded down $0.80 on Tuesday, reaching $32.03. 123,972 shares of the stock traded hands, compared to its average volume of 398,654. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The company's fifty day simple moving average is $29.70 and its 200 day simple moving average is $29.60. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of 26.29 and a beta of 0.64. The company has a current ratio of 1.08, a quick ratio of 1.01 and a debt-to-equity ratio of 3.30.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The business had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. During the same quarter in the previous year, the business posted $1.45 earnings per share. Collegium Pharmaceutical's quarterly revenue was up 22.7% compared to the same quarter last year. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical announced that its board has initiated a share buyback plan on Monday, July 7th that permits the company to buyback $150.00 million in shares. This buyback authorization permits the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its stock is undervalued.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.